Aldeyra Claims Success In Final Phase III For First-In-Class Dry Eye Drug
Both Co-Primary Endpoints Hit In TRANQUILITY-2
Executive Summary
The company plans to submit an NDA for reproxalap for dry eye disease based on the results and hailed the crossover trial design as unique in the therapeutic area.
You may also be interested in...
Dry Eye Crossover Study Could Allow Aldeyra A Quick Response To US FDA’s CRL For Reproxalap
Aldeyra’s bid to rely on a single Phase III trial after an initial one failed is rejected by FDA, but firm already has a special protocol assessment under review for a trial that could provide the symptom data it says agency needs to approve the RASP modulator in dry eye.
Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap
Aldeyra already has a special protocol assessment under review at the FDA for a trial to provide the symptom data the agency said is needed for approval of the RASP modulator in dry eye disease.
Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.